Association of Maternal and Fetal Single-Nucleotide Polymorphisms in Metalloproteinase (MMP1, MMP2, MMP3, and MMP9) Genes with Preeclampsia

Sakowicz, Agata; Lisowska, M; Biesiada, Lidia; Rybak-Krzyszkowska, Magda; Gach, Agnieszka; Sakowicz, B.; Grzesiak, Mariusz; Huras, Hubert; Pietrucha, Tadeusz

doi:10.1155/2018/1371425

Cited by 18 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the mechanism of CKI for the treatment of LC may be related to its regulation of PRKCA expression. MMP1 and MMP9 are matrix metalloproteinase (MMP) genes that belong to a large family of zinc-dependent endopeptidases [82, 83]. The upregulation of MMP has been shown in various types of solid cancers [84].…”

Section: Discussionmentioning

confidence: 99%

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Meng

Liu

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Compound Kushen Injection (CKI) is a Chinese patent drug that shows good efficacy in treating lung cancer (LC). However, its underlying mechanisms need to be further clarified. Methods. In this study, we adopted a network pharmacology method to gather compounds, predict targets, construct networks, and analyze biological functions and pathways. Moreover, molecular docking simulation was employed to assess the binding potential of selected target-compound pairs. Results. Four networks were established, including the compound-putative target network, protein-protein interaction (PPI) network of LC targets, compound-LC target network, and herb-compound-target-pathway network. Network analysis showed that 8 targets (CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9) may be the therapeutic targets of CKI in LC. In addition, molecular docking simulation indicated that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding activity with the corresponding compounds. Furthermore, enrichment analysis indicated that CKI might exert a therapeutic role in LC by regulating some important pathways, namely, pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer. Conclusions. This study validated and predicted the mechanism of CKI in treating LC. Additionally, this study provides a good foundation for further experimental studies and promotes the reasonable application of CKI in the clinical treatment of LC.

show abstract

Section: Discussionmentioning

confidence: 99%

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Meng

Liu

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…It has been shown that the expression levels of several genes [62,63], SMAD3 [64][65][66], MMP1 [66][67][68][69], MMP2 [70][71][72], MMP9 [72,73], and TIMP1/TIMP2 [74,75]. Previous reports have clearly demonstrated that MMP1, MMP2, and MMP9 are activated in the aortic disease [66][67][68][69][70][71][72]. However, the present study dem-onstrated that the expression levels of MMP1, MMP2, and MMP9 indicated no significant differences between CD14 + cells in Stanford type B AAD patients and normal volunteers, while TIMP1 and TIMP2 (inhibitor of MMPs) levels were decreased [73][74][75].…”

Section: Journal Of Immunology Researchmentioning

confidence: 99%

Characterization and Significance of Monocytes in Acute Stanford Type B Aortic Dissection

Lü

Tong

Wang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Acute aortic dissection (AAD) is one of the most common fatal diseases noted in vascular surgery. Human monocytes circulate in dynamic equilibrium and display a considerable heterogeneity. However, the role of monocytes in AAD remains elusive. In our recent study, we firstly obtained blood samples from 22 patients with Stanford type B AAD and 44 age-, sex-, and comorbidity-matched control subjects. And the monocyte proportions were evaluated by flow cytometry. Results showed that the percentage of total CD14+ monocytes in the blood samples of Stanford AAD patients was increased significantly compared with that of normal volunteers (P<0.0005), and the absolute numbers of CD14brightCD16+ and CD14brightCD16- monocytes both increased significantly regardless of the percentage of PBMC or CD14+ cells, while CD14dimCD16+ monocytes displayed the opposite tendency. However, the percentage of CD14+ cells and its three subsets demonstrated no correlation with D-dimer (DD) and C-reactive protein (CRP). Then, blood mononuclear cell (PBMC) samples were collected by Ficoll density gradient centrifugation, followed with CD14+ magnetic bead sorting. After the purity of CD14+ cells was validated over 90%, AAD-related genes were concentrated in CD14+ monocytes. There were no significant differences observed with regard to the mRNA expression levels of MMP1 (P=0.0946), MMP2 (P=0.3941), MMP9 (P=0.2919), IL-6 (P=0.4223), and IL-10 (P=0.3375) of the CD14+ monocytes in Stanford type B AAD patients compared with those of normal volunteers. The expression levels of IL-17 (P<0.05) was higher in Stanford type B AAD patients, while the expression levels of TIMP1(P<0.05), TIMP2(P<0.01), TGF-β1 (P<0.01), SMAD3 (P<0.01), ACTA2 (P<0.001), and ADAMTS-1 (P<0.001) decreased. The data suggested that monocytes might play an important role in the development of Stanford type B AAD. Understanding of the production, differentiation, and function of monocyte subsets might dictate future therapeutic avenues for Stanford type B AAD treatment and can aid the identification of novel biomarkers or potential therapeutic targets for decreasing inflammation in AAD.

show abstract

“…More specifically, a few groups have reported an association between this polymorphism and PE risk [ 23 , 24 , 25 ]. Indeed, six studies have found an association between the -1562 T allele and PE in Brazilian, United Kingdom, Dutch, Polish, and Iranian populations, although in small cohorts (less than 180 cases and 200 controls) [ 25 , 26 , 27 , 28 , 29 , 30 ]. Hence, it is important to repeat these studies in different populations and large cohorts, as the size of the cohort, ethnic variation and geographical location can contribute to the differences in -1562 T allele distribution.…”

Section: Introductionmentioning

confidence: 99%

MMP-2 and MMP-9 Polymorphisms and Preeclampsia Risk in Tunisian Arabs: A Case-Control Study

Gannoun

Raguema

Zitouni

et al. 2021

JCM

View full text Add to dashboard Cite

The abnormal production of matrix metalloproteinases (MMPs), especially MMP-9 and MMP-2, plays a pivotal role in hypertensive disorders of pregnancy, and as such, can influence the development of preeclampsia. These alterations may result from functional genetic polymorphisms in the promoter region of MMP-9 and MMP-2 genes, which modify MMP-9 and MMP-2 expression. We investigated the association of MMP-9 polymorphism rs3918242 (-1562 C>T) and MMP-2 polymorphism rs2285053 (-735 C>T) with the risk of preeclampsia. This case–control study was conducted on 345 women with preeclampsia and 281 age-matched women with normal pregnancies from Tunisian hospitals. Genomic DNA was extracted from whole blood collected at delivery. Genotypes for -1562 C>T and -735 C>T polymorphisms were performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). An increased frequency of heterozygous MMP-9 -1562 C/T genotype carriers was observed in women with preeclampsia compared to healthy controls (p = 0.03). In contrast, the MMP-2 -735 C>T polymorphism was not significantly different regarding frequency distribution of the allele and genotype between healthy pregnant women and women with preeclampsia. Our study suggests that the MMP-9 -1562 C/T variant, associated with high MMP-9 production, could be a genetic risk factor for preeclampsia in Tunisian women.

show abstract

Association of Maternal and Fetal Single-Nucleotide Polymorphisms in Metalloproteinase (MMP1, MMP2, MMP3, and MMP9) Genes with Preeclampsia

Cited by 18 publications

References 33 publications

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Characterization and Significance of Monocytes in Acute Stanford Type B Aortic Dissection

MMP-2 and MMP-9 Polymorphisms and Preeclampsia Risk in Tunisian Arabs: A Case-Control Study

Contact Info

Product

Resources

About